AI assistant
Adaptimmune Therapeutics PLC — Director's Dealing 2020
Apr 2, 2020
34721_dirs_2020-04-01_c682a340-b016-4dd3-b477-314534cba6ab.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2020-04-01
Reporting Person: Wood Gavin (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-04-01 | Option to purchase Ordinary Shares | $0.45 | A | 2500000 | Acquired | 2030-04-01 | Ordinary Shares (2500000) | Direct |
| 2020-04-01 | Option to purchase Ordinary Shares | $0.0012 | A | 565000 | Acquired | 2030-04-01 | Ordinary Shares (565000) | Direct |
Footnotes
F1: The exercise price was converted from GBP0.36 based on an exchange rate of U.S.$1.245481 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F2: Exercisable as to 625,000 Ordinary Shares on April 1, 2021 and will be exercisable as to the remainder in monthly installments of 52,080 Ordinary Shares on the first of each month from May 1, 2021 through March 1, 2024 and 52,200 Ordinary Shares on April 1, 2024.
F3: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.245481 to GBP1.00. The actual exercise price will be the pounds sterling amount.
F4: Exercisable as to 141,250 Ordinary Shares on April 1, 2021 and will be exercisable as to the remainder in annual installments of 141,250 Ordinary Shares on the first of each April from April 1, 2022 through April 1, 2024.